开云app官网登录入口网页版-官方正版

#阿达木#

86篇内容 | 2425人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1615670, encodeId=303a16156e066, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=J Invest Dermatol：阿达木单抗联合低剂量甲氨蝶呤能更好的治疗银屑病, objectType=article, longId=737610, objectId=fb35e37610bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb35e37610bb, replyNumber=0, likeNumber=86, createdTime=2022-09-03, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb35e37610bb, moduleTitle=J Invest Dermatol：阿达木单抗联合低剂量甲氨蝶呤能更好的治疗银屑病, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=fb35e37610bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615668, encodeId=0f1c1615668a4, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=君实生物阿达木单抗增加适应症补充申请获得受理, objectType=article, longId=737115, objectId=5ce7e37115c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ce7e37115c5, replyNumber=0, likeNumber=82, createdTime=2022-08-28, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ce7e37115c5, moduleTitle=君实生物阿达木单抗增加适应症补充申请获得受理, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5ce7e37115c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615669, encodeId=407a1615669f6, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=Am J Clin Dermatol：阿达木单抗和其仿制药（BI 695501）的疗效对比, objectType=article, longId=736667, objectId=8f0ae36667ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f0ae36667ef, replyNumber=0, likeNumber=122, createdTime=2022-08-24, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f0ae36667ef, moduleTitle=Am J Clin Dermatol：阿达木单抗和其仿制药（BI 695501）的疗效对比, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8f0ae36667ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615667, encodeId=546b161566e80, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=Lancet：乌司奴单抗 vs 阿达木单抗治疗克罗恩病头对头研究结果出炉, objectType=article, longId=729675, objectId=dbcee2967524, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbcee2967524, replyNumber=0, likeNumber=126, createdTime=2022-06-17, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbcee2967524, moduleTitle=Lancet：乌司奴单抗 vs 阿达木单抗治疗克罗恩病头对头研究结果出炉, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=dbcee2967524)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615666, encodeId=966d16156665d, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=Heidelb:阿达木和司库奇尤治疗银屑病患者的结核病阳性转换率研究, objectType=article, longId=728032, objectId=4973e28032a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4973e28032a7, replyNumber=0, likeNumber=98, createdTime=2022-05-29, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4973e28032a7, moduleTitle=Heidelb:阿达木和司库奇尤治疗银屑病患者的结核病阳性转换率研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4973e28032a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615665, encodeId=9cf91615665ff, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=J Invest Dermatol：阿达木单抗联合甲氨蝶呤与阿达木单抗单药治疗银屑病疗效对比, objectType=article, longId=301378, objectId=829a3013e89e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=829a3013e89e, replyNumber=0, likeNumber=96, createdTime=2022-03-23, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=829a3013e89e, moduleTitle=J Invest Dermatol：阿达木单抗联合甲氨蝶呤与阿达木单抗单药治疗银屑病疗效对比, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=829a3013e89e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615664, encodeId=972c16156644a, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=阿达木单抗能否复制“药王”神话？, objectType=article, longId=300645, objectId=789230064527, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=789230064527, replyNumber=0, likeNumber=126, createdTime=2022-03-14, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=789230064527, moduleTitle=阿达木单抗能否复制“药王”神话？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=789230064527)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615663, encodeId=db961615663af, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=JEADV：阿达木单抗治疗银屑病会不会引起肠道微生物群的变化？, objectType=article, longId=299907, objectId=4a1929990e86, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a1929990e86, replyNumber=0, likeNumber=84, createdTime=2022-03-03, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a1929990e86, moduleTitle=JEADV：阿达木单抗治疗银屑病会不会引起肠道微生物群的变化？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4a1929990e86)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615662, encodeId=67db161566294, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=BioDrugs：AVT02 VS. 原研药阿达木单抗在中重度慢性斑块状银屑病患者中的疗效、安全性和免疫原性, objectType=article, longId=293607, objectId=125629360edc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=125629360edc, replyNumber=0, likeNumber=90, createdTime=2022-01-09, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=125629360edc, moduleTitle=BioDrugs：AVT02 VS. 原研药阿达木单抗在中重度慢性斑块状银屑病患者中的疗效、安全性和免疫原性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=125629360edc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615661, encodeId=28811615661e2, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=Clinical Translational Gastroenterology：克罗恩病患者接受诱导治疗后高阿达木单抗药物水平可在第24周仍保持患者的生物缓解, objectType=article, longId=219255, objectId=ce6b219255e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce6b219255e2, replyNumber=0, likeNumber=102, createdTime=2021-10-27, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce6b219255e2, moduleTitle=Clinical Translational Gastroenterology：克罗恩病患者接受诱导治疗后高阿达木单抗药物水平可在第24周仍保持患者的生物缓解, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ce6b219255e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615660, encodeId=92951615660c1, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=美国FDA批准 Cyltezo（阿达木单抗-adbm）作为第一个可与Humira互换的生物仿制药, objectType=article, longId=218852, objectId=2c2e218852d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c2e218852d4, replyNumber=0, likeNumber=135, createdTime=2021-10-20, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c2e218852d4, moduleTitle=美国FDA批准 Cyltezo（阿达木单抗-adbm）作为第一个可与Humira互换的生物仿制药, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2c2e218852d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615659, encodeId=71d31615659e8, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=Clin Trans Gastroenterology:诱导治疗后高阿达木单抗药物水平可预测克罗恩病患者第 24 周的疾病生物学缓解, objectType=article, longId=218242, objectId=cbb32182425b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbb32182425b, replyNumber=0, likeNumber=86, createdTime=2021-10-10, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbb32182425b, moduleTitle=Clin Trans Gastroenterology:诱导治疗后高阿达木单抗药物水平可预测克罗恩病患者第 24 周的疾病生物学缓解, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=cbb32182425b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615658, encodeId=c88a1615658df, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=ARD:评估Taltz(ixekizumab)与阿达木单抗治疗银屑病关节炎患者的疗效和安全性, objectType=article, longId=216821, objectId=a6d72168217e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6d72168217e, replyNumber=0, likeNumber=78, createdTime=2021-09-09, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6d72168217e, moduleTitle=ARD:评估Taltz(ixekizumab)与阿达木单抗治疗银屑病关节炎患者的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a6d72168217e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615657, encodeId=a2b0161565e73, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle= JAMA Surg：手术联合阿达木单抗治疗中重度化脓性汗腺炎, objectType=article, longId=216270, objectId=1f2f2162e0c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f2f2162e0c0, replyNumber=0, likeNumber=75, createdTime=2021-08-26, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f2f2162e0c0, moduleTitle= JAMA Surg：手术联合阿达木单抗治疗中重度化脓性汗腺炎, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1f2f2162e0c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615656, encodeId=2527161565615, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=NEJM：Bimekizumab与阿达木单抗对斑块状银屑病的疗效比较，王者诞生？, objectType=article, longId=213912, objectId=0cae21391291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cae21391291, replyNumber=0, likeNumber=0, createdTime=2021-07-09, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cae21391291, moduleTitle=NEJM：Bimekizumab与阿达木单抗对斑块状银屑病的疗效比较，王者诞生？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0cae21391291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615655, encodeId=a5f6161565548, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=Dig Dis Sci：高抗英夫利昔单抗抗体滴度不会影响炎症性肠病患者接受阿达木单抗治疗的反应, objectType=article, longId=213405, objectId=00a4213405fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a4213405fc, replyNumber=0, likeNumber=112, createdTime=2021-06-30, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a4213405fc, moduleTitle=Dig Dis Sci：高抗英夫利昔单抗抗体滴度不会影响炎症性肠病患者接受阿达木单抗治疗的反应, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=00a4213405fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615654, encodeId=a1c31615654f5, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=J Gastroenterology：富含亮氨酸的α-2糖蛋白是监测阿达木单抗治疗炎性肠病疾病活动的潜在生物标志物, objectType=article, longId=210919, objectId=c324210919be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c324210919be, replyNumber=0, likeNumber=121, createdTime=2021-05-08, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c324210919be, moduleTitle=J Gastroenterology：富含亮氨酸的α-2糖蛋白是监测阿达木单抗治疗炎性肠病疾病活动的潜在生物标志物, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c324210919be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615653, encodeId=4ae31615653fb, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=NEJM：Bimekizumab vs 阿达木单抗治疗中重度斑块性银屑病, objectType=article, longId=210416, objectId=17a3210416be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17a3210416be, replyNumber=0, likeNumber=68, createdTime=2021-04-26, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17a3210416be, moduleTitle=NEJM：Bimekizumab vs 阿达木单抗治疗中重度斑块性银屑病, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=17a3210416be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615652, encodeId=074b16156529b, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=NEJM：Upadacitinib治疗银屑病关节炎疗效优于阿达木单抗, objectType=article, longId=209559, objectId=afa5209559ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afa5209559ff, replyNumber=0, likeNumber=121, createdTime=2021-04-06, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afa5209559ff, moduleTitle=NEJM：Upadacitinib治疗银屑病关节炎疗效优于阿达木单抗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=afa5209559ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615651, encodeId=31071615651bb, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, objectTitle=Ann Rheum Dis：类风湿性关节炎换用阿达木单抗或乌帕替尼治疗的疗效和安全性, objectType=article, longId=208557, objectId=2da320855e15, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2da320855e15, replyNumber=0, likeNumber=87, createdTime=2021-03-19, rootId=0, userName=1179102698_36768932, userId=3dba19658752, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2da320855e15, moduleTitle=Ann Rheum Dis：类风湿性关节炎换用阿达木单抗或乌帕替尼治疗的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2da320855e15)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

阿达木

2020-05-29

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

J Invest Dermatol：阿达木单抗联合低剂量甲氨蝶呤能更好的治疗银屑病

2022-09-03

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

君实生物阿达木单抗增加适应症补充申请获得受理

2022-08-28

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

Am J Clin Dermatol：阿达木单抗和其仿制药（BI 695501）的疗效对比

2022-08-24

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

Lancet：乌司奴单抗 vs 阿达木单抗治疗克罗恩病头对头研究结果出炉

2022-06-17

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

Heidelb:阿达木和司库奇尤治疗银屑病患者的结核病阳性转换率研究

2022-05-29

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

J Invest Dermatol：阿达木单抗联合甲氨蝶呤与阿达木单抗单药治疗银屑病疗效对比

2022-03-23

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

阿达木单抗能否复制“药王”神话？

2022-03-14

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

JEADV：阿达木单抗治疗银屑病会不会引起肠道微生物群的变化？

2022-03-03

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

BioDrugs：AVT02 VS. 原研药阿达木单抗在中重度慢性斑块状银屑病患者中的疗效、安全性和免疫原性

2022-01-09

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

Clinical Translational Gastroenterology：克罗恩病患者接受诱导治疗后高阿达木单抗药物水平可在第24周仍保持患者的生物缓解

2021-10-27

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

美国FDA批准 Cyltezo（阿达木单抗-adbm）作为第一个可与Humira互换的生物仿制药

2021-10-20

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

Clin Trans Gastroenterology:诱导治疗后高阿达木单抗药物水平可预测克罗恩病患者第 24 周的疾病生物学缓解

2021-10-10

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

ARD:评估Taltz(ixekizumab)与阿达木单抗治疗银屑病关节炎患者的疗效和安全性

2021-09-09

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

JAMA Surg：手术联合阿达木单抗治疗中重度化脓性汗腺炎

2021-08-26

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

NEJM：Bimekizumab与阿达木单抗对斑块状银屑病的疗效比较，王者诞生？

2021-07-09

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

Dig Dis Sci：高抗英夫利昔单抗抗体滴度不会影响炎症性肠病患者接受阿达木单抗治疗的反应

2021-06-30

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

J Gastroenterology：富含亮氨酸的α-2糖蛋白是监测阿达木单抗治疗炎性肠病疾病活动的潜在生物标志物

2021-05-08

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

NEJM：Bimekizumab vs 阿达木单抗治疗中重度斑块性银屑病

2021-04-26

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

NEJM：Upadacitinib治疗银屑病关节炎疗效优于阿达木单抗

2021-04-06

1179102698_36768932 (审核中...)

前往app查看评论内容

#阿达木#

Ann Rheum Dis：类风湿性关节炎换用阿达木单抗或乌帕替尼治疗的疗效和安全性

2021-03-19

科室
- - 订阅+
  - 更多科室
工具
服务